Series A expected to advance lead asset Mucosal-Immune Modulator CS-0003 through Phase II in GI surgical site infections and expand a differentiated GI mucosal-immune pipeline and metabolomics-driven discovery platform NORTH CHICAGO, Ill.–(BUSINESS WIRE)–32 Biosciences, a…
North Chicago, Illinois — According to state and local development sources, AbbVie plans to invest $195,000,000.00 to expand in North Chicago. The company plans to occupy the new space at 1401 Sheridan Rd in North…
Microbiome-focused company receives $6 million in funding to advance gut microbiome platform technologies NORTH CHICAGO, Ill.–(BUSINESS WIRE)–32 Biosciences, a leader in the field of gut microbiome medicine, today announced it has received $6 million in funding…